Agenus
Agenus' revenue rose 10.4% to $114 million in fiscal 2025. Its operating margin was −17.7%, up from −116.4% a year earlier. Free cash flow was −$77 million. The diluted share count rose 38.5%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Agenus does
Agenus is a clinical-stage biotechnology company, which means it has no approved products yet. It develops immunotherapies for cancer and infectious disease. Immunotherapies are treatments that help the body's immune system fight disease.
Its main business is immuno-oncology, using antibodies to activate the immune system against tumors. Its lead program is botensilimab, alone and combined with balstilimab. With the Canadian Cancer Trials Group, it is running a global Phase 3 trial of the combination against best supportive care in refractory colorectal cancer. In France, a national access program lets eligible patients get the combination in hospitals, reimbursed by the national health system.
After a strategic realignment announced in December 2024, Agenus put its resources behind the botensilimab and balstilimab program and paused some other early work while it looks at partnering and funding. It also holds an equity investment in MiNK Therapeutics and a majority stake in SaponiQx, a vaccine adjuvant business. Its stock trades on the Nasdaq Capital Market.
Its biggest risks, as it describes them
- Net losses so far and expected in the future, and a need for additional financing to finish development.
- Its auditor's report raises doubt about its ability to continue as a going concern.
- Its business depends heavily on the success of botensilimab and its combination therapy programs.
- Trials could show serious side effects or too little benefit, and enrolling patients could prove difficult.
Income statement
Agenus lost money in fiscal 2025: a net loss of $3 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 307 | 193 | 76 | 40 | 3 |
| Debt incl. finance leases | 14 | 13 | 13 | 38 | 45 |
| Net debt (negative means net cash) | −293 | −180 | −63 | −2 | 42 |
| Net debt to EBITDA | −9.0x | — | — | — | — |
| Debt to equity | 0.4x | — | — | — | — |
| Interest coverage | 22.4x | −2.8x | −1.5x | −1.0x | −0.4x |
| Current ratio | 2.1x | 1.1x | 0.4x | 0.2x | 0.4x |
| Quick ratio | 2.1x | 1.1x | 0.4x | 0.2x | 0.4x |
Cash flow
Projections
Project Agenus' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
What Agenus says to expect
- Cash: funding of planned operations
Based on the current operating plan, the upfront proceeds are expected to support ROBBIN initiation, regulatory activities and operations through the third quarter of 2027. Assuming full exercise of the warrants, the financing is expected to support the planned ROBBIN program and company operations through year-end 2031.
Insider trades
No officer, director or 10% owner of Agenus reported buying or selling its shares on the open market between November 20, 2025 and November 19, 2026.
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 3 of 9 | 2 of 9 | 3 of 9 |
| Rule of 40 | −90.3% | −187.4% | −57.2% |
| Altman Z'' | −27.06 | −40.73 | −38.05 |
| Accruals ratio | −9.1% | −27.4% | 32.7% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Fail | Fail | Pass |
| Cash from operations exceeds net income | Pass | Pass | Fail |
| Debt fell relative to assets | Fail | Fail | Fail |
| Current ratio rose | Fail | Fail | Pass |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | Pass | Pass | Fail |
| Revenue rose relative to assets | Pass | Fail | Pass |
| F-score | 3 of 9 | 2 of 9 | 3 of 9 |
Compare
Put Agenus side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Agenus | FY25 | 10.4% | −17.7% | −67.6% | — | — | 3 | |
| ImmunityBio | FY25 | 668.3% | −226.0% | −272.6% | — | — | 3 | Compare |
| Century Therapeutics | FY25 | 1,556.8% | −15.8% | −95.9% | — | — | — | Compare |
| Atara Biotherapeutics | FY25 | −6.3% | 29.7% | −42.2% | — | — | — | Compare |
| Monte Rosa Therapeutics | FY25 | 63.5% | −43.8% | −22.2% | — | — | — | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 23 | 43 | 37 | 150 | 88 | 296 | 98 | 156 | 104 | 114 |
| Revenue growth | −9.0% | 90.0% | −14.2% | 307.9% | −41.2% | 235.3% | −66.8% | 59.5% | −33.8% | 10.4% |
| Gross profit | — | — | — | — | 86 | 292 | 88 | 153 | 103 | 113 |
| Research and development | 95 | 116 | 125 | 168 | 143 | 179 | 187 | 235 | 156 | 79 |
| Operating income | −108 | −104 | −124 | −70 | −117 | 26 | −179 | −160 | −120 | −20 |
| Net income | −127 | −121 | −162 | −112 | −183 | −29 | −231 | −257 | −232 | −3 |
| Diluted EPS (US$) | −0.03 | −0.02 | −0.03 | −0.02 | −0.02 | −0.00 | −15.64 | −13.75 | −10.59 | 0.00 |
| Diluted shares (millions) | 4,354 | 4,921 | 5,539 | 6,749 | 8,625 | 11 | 14 | 18 | 22 | 30 |
| Cash flow | ||||||||||
| Cash from operations | −80 | −94 | −131 | −19 | −139 | 10 | −175 | −224 | −158 | −77 |
| Capital expenditure | 12 | 3 | 4 | 5 | 4 | 34 | 53 | 10 | 1 | 0 |
| Free cash flow | −92 | −97 | −135 | −23 | −143 | −24 | −228 | −234 | −159 | −77 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 1 | 0 | 3 | 0 | 0 | 0 |
| Stock-based compensation | 13 | 12 | 8 | 10 | 10 | 20 | 18 | 23 | 17 | 14 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 76 | 60 | 53 | 62 | 100 | 307 | 193 | 76 | 40 | 3 |
| Debt incl. finance leases | 131 | 163 | 13 | 14 | 20 | 14 | 13 | 13 | 38 | 45 |
| Total assets | 157 | 138 | 136 | 155 | 214 | 466 | 414 | 314 | 226 | 227 |
| Total liabilities | 196 | 214 | 311 | 387 | 426 | 418 | 468 | 462 | 533 | 505 |
| Shareholders' equity | −39 | −76 | −172 | −225 | −204 | 34 | −61 | −160 | −326 | −271 |
| Margins and ratios | ||||||||||
| Gross margin | — | — | — | — | 97.3% | 98.8% | 89.2% | 98.0% | 99.5% | 99.1% |
| Operating margin | −476.1% | −242.1% | −336.6% | −46.7% | −133.0% | 8.7% | −183.0% | −102.1% | −116.4% | −17.7% |
| Net margin | −562.6% | −281.5% | −440.5% | −74.3% | −207.4% | −9.7% | −235.3% | −164.7% | −224.5% | −2.7% |
| Free cash flow margin | −409.7% | −227.0% | −366.2% | −15.6% | −161.7% | −8.0% | −233.0% | −149.8% | −153.6% | −67.6% |
| Rule of 40 (growth + FCF margin) | −418.7% | −137.1% | −380.4% | 292.4% | −202.9% | 227.3% | −299.9% | −90.3% | −187.4% | −57.2% |
| Return on capital | — | −388.9% | — | — | — | — | — | — | — | — |
| Return on equity | −803.7% | — | — | — | — | — | — | — | — | — |
| Return on assets | −63.6% | −81.7% | −117.9% | −76.5% | −98.9% | −8.4% | −52.5% | −70.8% | −86.0% | −1.4% |
| Net debt to EBITDA | — | — | — | — | — | −9.0x | — | — | — | — |